On the Mission to Unleash the Full Power of ICB in Cancer
Through immunotherapies utilising Immune Checkpoint Blockers (ICB), advanced solid cancers can today be treated with unprecedented efficacy. However, not all patients respond positively to these treatments. InFLAMES researcher, Docent Carlos Rogerio Figueiredo and his team are working to uncover the underlying causes of this resistance to ICB. They focus on patients suffering from malignant melanomas and lung cancers as main research models.